Keryx Biopharmaceuticals Inc. (Nasdaq: KERX) and Aeterna Zentaris (Nasdaq: AEZS) reported that their colorectal cancer treatment Perifosine failed a Phase 3 clinical trial. Shares of Keryx plummeted $3.30 to $1.68 while Aeterna stock plunged $1.39 to $0.75.
Drug Trial Failure For Keryx And Aeterna
April 02, 2012 at 13:01 PM EDT
